Since the previous IP portfolio update on
The new patent grants and Notices of Allowance are summarized below.
Patent Protection | Description | Market | Patent No. | Status |
Composition of Matter | For certain deuterated homologues of certain tryptamine compounds | 11,578,039 | Granted | |
For certain deuterated homologues of certain tryptamine compounds | New Zealand | 788543 | Granted | |
For certain deuterated analogues of N,N, dimethyltryptamine (“DMT”) | GB | 2 592 822 | Grant expected after May 22, 2023 | |
For a group of deuterated homologues of DMT | 11,660,289 | Grant expected on | ||
For a group of deuterated homologues of DMT | 4 031 529 | Notice of Allowance | ||
Medical Use | Of certain deuterated analogues of DMT | GB | 2 586 940 | Grant expected after |
Medical use and therapeutic compositions of a group of deuterated homologues of DMT | 2021204158 | Notice of Allowance | ||
Medical use and therapeutic compositions of a group of deuterated homologues of DMT | 794833 | Notice of Allowance | ||
Therapeutic compositions of a group of deuterated homologues of DMT | 2022-574099 | Notice of Allowance | ||
Drug Product | Novel optimized injectable formulation of DMT based compounds | 2021334933 | Granted | |
Therapeutic solid dosage forms of deuterated DMT analogues | GB | 2 595 776 | Granted | |
Synthetic Route | Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale | 11,643,390 | Granted | |
Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale | 3160337 | Notice of Allowance |
As of
Candidate / Project | Relevant Patents in Portfolio (No. active patents / pending patent applications) |
SPL0261, SPL0282, SPL0293 | 4 granted patents and 31 allowed and pending applications |
SPL028 | 6 granted patents, 37 allowed and pending applications |
SPL028, SPL029 | 8 allowed and pending applications |
SPL029 | 4 granted patents, 11 allowed and pending applications |
Non-psychedelic / other | 5 granted patents, 10 allowed and pending applications |
1Intravenous or intramuscular DMT
2 Injectable deuterated DMT series
3 Oral tryptamine series
About
Contact Information:
Email: ir@smallpharma.co.uk
Tel: +44 (0)7720 326 847
Media Relations:
Email: jenny.maguire@smallpharma.co.uk
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this news release include statements regarding the granting of, and protections afforded by, three patents expected to be granted by
In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting the Company’s business and results of operations; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.
The
Source:
2023 GlobeNewswire, Inc., source